Background/Aims: Bronchiectasis is aggravated by gastroesophageal reflux disease (GERD) owing to micro aspiration. Some researchers note the effect of antireflux surgery in bronchiectasis with GERD. However, few have investigated the effects of medical antireflux therapy. We investigated the effect of proton pump inhibitors (PPIs) in bronchiectasis with GERD. Methods: From March 2003 to May 2015, the clinical records of patients who had bronchiectasis with GERD were reviewed. Patients underwent an initial pulmonary function test (PFT) and chest computed tomography when diagnosed with bronchiectasis. One group with typical GERD symptoms was treated with PPIs, while the other group was not. Both groups underwent PFTs within six months after completing PPI therapy. Population characteristics and associations were compared between the groups. Results: Two hundred and fifty-seven patients (124 male, 133 female; mean age 67.6±10.0 years) were included. There were no significant differences between the groups in terms of forced vital capacity (FVC; p=0.239), forced expiratory volume in one second (FEV1; p=0.555), or FEV1/FVC (p=0.374) after PPI therapy. However, there were significant improvements in FVC (p=0.002) and FEV1 (p=0.006) in patients with high BMI in the PPI treatment group. Conclusions: PPIs have no effect on the pulmonary function in patients with bronchiectasis and GERD. However, PPIs were noted to produce improvements in lung function in patients with bronchiectasis and high BMI. (Korean J Gastroenterol 2016;68:10-15) 
INTRODUCTION
Bronchiectasis is a chronic dilatation of the airways with thickening of the bronchial walls, which typically presents with chronic cough and sputum hypersecretion. 1 Studies from the USA estimate a prevalence of 4.2 per 100,000 people among those aged 18 to 34 years, which increases to 271.8 per 100,000 among people aged more than 75 years. 2 Several etiologies, ranging from idiopathic to congenital diseases, systemic diseases (e.g., autoimmune disease such as rheumatoid arthritis), and post-infective causes, have been implicated. cated by the coexistence of other conditions, including gastroesophageal reflux disease (GERD). 4, 5 The prevalence of GERD in patients with bronchiectasis was approximately 40% according to Lee et al. 6 in 2014, compared to 18% in the control group. GERD has an inverse relationship with lung function tests in bronchiectatic patients. 4 Bronchiectasis is aggravated by GERD due to vagally mediated reflex bronchoconstriction and pulmonary micro aspiration. 7 Research on the effect of antireflux surgery in bronchiectasis patients with GERD 8, 9 finds that after surgery, respiratory symptoms and pulmonary function improves. 8, 9 However, few studies have investigated the effects of antireflux medication. The purpose of this study was to determine the effect of proton pump inhibitors (PPIs) among the antireflux medical therapies in patients with bronchiectasis and GERD. Table 2 ).
SUBJECTS AND METHODS
We assessed the associations of factors such as age, BMI, and comorbid conditions, with the patients' pulmonary function parameters. In the PPI treatment group, FVC (rs=0.564, p=0.002) and FEV1 (rs=0.513, p=0.006) improved significantly from the pre-treatment values in patients with increased BMI. Improvements of changes in FVC (rs=0.568, p=0.002) and FEV1 (rs=0.501, p=0.008) in the PPI treatment group were significantly related to severity of obesity.
This was not observed in the non-PPI treatment group.
However, it was also noted that changes in FVC (rs=−0.427, p=0.026) were significantly worse in patients in the PPI treatment group with a history of pulmonary tuberculosis (Table   3 , Fig. 1 
.208, p=0.017) also significantly associated with the severity of obesity (Table 4) .
DISCUSSION
The role of GERD in the pathogenesis of respiratory symptoms and diseases has been discussed. There is a high prevalence of reflux in asthma and chronic cough, which may be induced through different mechanisms, including micro aspiration and reflex bronchoconstriction. 7, 10, 11 Refluxed gastric material reaches the proximal esophagus and moves into
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GERD may also cause bronchiectasis in the adult population. 4 In a study of four patients with severe bronchiectasis who completed dual-channel esophageal pH monitoring, the prevalence of distal reflux in 75% and proximal reflux in 50% suggests that patients with more severe bronchiectasis may be more likely to have GERD. 13 Helicobacter pylori has been identified in tracheobronchial secretions, and a high seroprevalence is noted in patients with bronchiectasis. 14 H. pylori produces a wide range of toxins including urease, phospholipidases, alcohol dehydrogenase, hemolysin, platelet-activating factor, and mucolytic factor. 15 These toxins are harmful to the stomach and duodenum, and act by generation of an intense immune response, resulting in submucosal lymphocyte and neutrophil infiltration. They can likewise interact with other tissues. 16 Aspiration or inhalation of H. pylori exotoxins may contribute to chronic airway inflammation in patients with idiopathic bronchiectasis. 14 Longstanding respiratory disease related to GERD has negative effects on lung functions. 9, 12 Active antireflux interventions, such as laparoscopic fundoplication, Stretta radiofrequency, and cruroraphy, can prevent aggravation of chronic lung disease with bronchiectasis. 8, 9 Several studies have noted improvements in lung function after these surgical procedures. 8, 9 Pasteur et al. 17 found GERD to be a cause in 4% of patients, based on gastrointestinal symptoms and symptomatic improvement after antireflux therapy. In the present study, we assessed the effect of PPIs among the antireflux medications on the lung function of patients with bronchiectasis. We compared the differences in lung function parameters before and after PPIs between the treatment and the control groups.
There were no statistically significant differences in lung function tests between groups. However, we observed statistically significant improvements between the pre-PPI and the post-PPI FVC and between the pre-PPI and the post-PPI FEV1 based on BMI. Thus, although PPIs did not significantly change pulmonary function parameters in patients with bronchiectasis and GERD, there were statistically significant improvements in certain subgroups, specifically obese individuals. This is believed to result from obesity causing increased esophageal acid exposure time compared to the non-obese population. 18 As antireflux surgery is an anatomical repair, it prevents the reflux of both acid and non-acid materials. PPIs, however, only prevent the reflux of acids. This may be why the lung parameters did not differ by PPI treatment.
This study has some limitations. First, this study is retrospective. The retrospective study design was non-randomized study. Furthermore, the PPI treatment duration varied from 22 days to 1,784 days in the PPI treatment group.
In conclusion, we were unable to reject the null hypothesis that PPIs have no effect on the pulmonary function in patients with bronchiectasis and GERD. We attribute this to the fact that unlike antireflux surgery, PPIs are unable to prevent nonacid materials from refluxing. However, PPIs do produce improvements in lung function in patients with bronchiectasis and higher BMI in accordance with the severity of obesity.
This could be because obesity causes increased esophageal acid exposure time. Future studies are required with larger sample sizes and a randomized prospective design to determine the effects of antireflux medical therapy in obese patients with bronchiectasis and GERD.
